What we do

Subscribe to
our newsletter!

Subscribe here

Factsheets

MPE has developed a series of factsheets for patients and patient advocates covering treatment for myeloma and AL amyloidosis. These publications contain essential information about treatments and medicines, so that patients can feel safe and informed when asking their doctor specific questions. There is also a PDF version with all the information available to download. Check out the following factsheets on:

Melphalan flufenamide

Melphalan flufenamide is derived from the chemotherapeutic agent melphalan. It is indicated for treating adult myeloma patients with dexamethasone.

Teclistamab

Teclistamab is a laboratory-made, bispecific monoclonal antibody (BsAb).

Ciltacabtagene autoleucel

Ciltacabtagene autoleucel (also known as cilta-cel or Carvykti®) is a chimeric antigen receptor T-cell therapy (CAR T-cell therapy).

Idecabtagene vicleucel

Idecabtagene vicleucel is a type of CAR-T therapy.

Isatuximab

Isatuximab is a monoclonal antibody (mAb, a laboratory manufactured antibody) drug.

Selinexor

Selinexor is a first-in-class selective inhibitor of nuclear export (SINE) drug.

Thalidomide

Thalidomide is approved in combination with melphalan and prednisone (VMp) in patients with newly diagnosed myeloma.

Lenalidomide

Lenalidomide is a cancer medicine approved in Europe in 2007 for the treatment of myeloma.

Pomalidomide

Pomalidomide is an anti-cancer medicine approved in Europe since 2013.

Bortezomib

Bortezomib is a cancer medicine approved in Europe in 2012 for the treatment of adult patients with myeloma.

Daratumumab

Daratumumab is a monoclonal antibody approved in Europe since 2016 for use in myeloma patients.

Panobinostat

Panobinostat is a cancer medicine that was approved in Europe in 2015.

Elotuzumab

Elotuzumab is a monoclonal antibody.

Ixazomib

Ixazomib is the first oral proteasome inhibitor to treat adults with myeloma.

Carfilzomib

Carfilzomib is a cancer medicine approved in Europe in 2015 for the treatment of relapsed and/or refractory myeloma.

Amyloidosis

Amyloidosis refers to a group of diseases characterised by the accumulation of an abnormal protein called amyloid, which builds up in tissues and organs.

Belantamab mafodotin

Belantamab mafodotin is a first-in-class antibody drug conjugate approved in Europe in 2020 for use in myeloma patients.

Stem cell transplant

Myeloma is a rare cancer of the bone marrow. It is due to the formation of abnormal plasma cells, also called myeloma cells, which divide uncontrollably.